DCM
ALT icon

Deuterium Capital Management’s Altimmune ALT Stock Holding History

Deuterium Capital Management’s Portfolio ALT Stock Details ALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-10,000
Closed -$113K – 57
2023
Q4 		$113K Buy
+10,000
New +$41.8K 0.37% 34

Other funds holding ALT

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Deuterium Capital Management's ALT Position: Q1 2024 in Review

Deuterium Capital Management sold out of Altimmune (ALT) in Q1 2024, closing a stake of 10,000 shares — an estimated $113K sold.

Deuterium Capital Management first reported a position in ALT in Q4 2023 and held it in 1 quarter. The position peaked at $113K in Q4 2023. 172 funds tracked by Wall St. Rank hold ALT as of Q1 2024.

  • Deuterium Capital Management reported no remaining Altimmune position as of Q1 2024 after selling out during the quarter.
  • Deuterium Capital Management sold 10,000 Altimmune shares in Q1 2024, an estimated $113K.
  • Deuterium Capital Management first reported a position in Altimmune in Q4 2023 and held it in 1 quarter.
  • Deuterium Capital Management's Altimmune position peaked at $113K in Q4 2023.
  • 172 funds tracked by Wall St. Rank held Altimmune as of Q1 2024.

Based on Deuterium Capital Management's 13F filing for Q1 2024, filed 6 May 2024.